UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 3)*

Rennova Health, Inc.

(Name of Issuer)

Common Stock, $.01 par value

(Title of Class of Securities)

759757 10 7

(CUSIP Number)

Steven Sramowicz

400 South Australian Avenue, 8^th Floor

West Palm Beach, Florida 33401

(561) 855-1626

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

September 21, 2016

(Date of Event which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box o.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosure provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Item 1.          Security and Issuer

This Amendment No. 3 to Schedule 13D amends the Statement on Schedule 13D, dated November 2, 2015, as previously amended by Amendments No. 1 and No. 2 to Schedule 13D, with respect to the Common Stock, $0.01 par value per share (the "Shares"), of Rennova Health, Inc., a Delaware corporation (the "Issuer"), filed by Steven Sramowicz. Except as expressly amended below, the Schedule 13D, dated November 2, 2015, as previously amended, remains in effect.

Item 3.          Source and Amount of Funds or Other Consideration

Item 3 is hereby amended to include the following:

This Amendment No. 3 to Schedule 13D is being filed to report the issuance to Mr. Sramowicz on September 21, 2016 of 1,146,789 Shares upon conversion of 1,000 shares of the Issuer’s Series B Convertible Preferred Stock owned of record by Mr. Sramowicz.

Item 5.          Interest in Securities of the Issuer

Item 5 is hereby amended to include the following:

As of September 21, 2016, Mr. Sramowicz may be deemed to beneficially own 6,032,802 Shares (or approximately 10.5% of the total number of Shares then deemed outstanding), which consists of (i) 3,517,625 Shares; (ii) 2,000,000 stock options owned of record by Mr. Sramowicz to purchase a like number of Shares; and (iii) 515,177 warrants owned of record by Mr. Sramowicz to purchase a like number of Shares, all as to which Mr. Sramowicz has sole dispositive and voting power.

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.